CPT code 81228: Genome-wide cytogenomic microarray analysis

CPT code 81228 is the procedure code for cytogenomic constitutional microarray analysis, which detects copy number variants across the genome in a germline specimen. It covers copy number analysis only. Its neighbor, 81229, adds SNP genotyping for loss of heterozygosity and uniparental disomy. Most 81228 denials come down to three issues: Missing prior authorization, a diagnosis outside the payer’s coverage criteria, and confusion with 81229.

Key takeaways

CPT code 81228 covers constitutional cytogenomic microarray analysis for copy number variants only. SNP genotyping for LOH or UPD is billed as 81229.

Medicare coverage is governed by MAC-issued Local Coverage Determinations. Accepted indications include intellectual disability, developmental delay, autism spectrum disorder, and congenital anomalies.

Many commercial and Medicare Advantage payers require prior authorization for 81228, and a missing one is the most common denial reason.

Pabau’s claims management software connects to the Claim.MD clearinghouse to validate CPT and ICD-10 codes before submission, cutting preventable denials on codes like 81228.

CPT code 81228: Official descriptor and what the procedure covers

CPT code 81228 is a Tier 1 molecular pathology code. It sits within the 81200-81383 Tier 1 molecular pathology range of the CPT code set. The American Medical Association (AMA) sets its official descriptor, quoted word for word in the table below in its two CPT parts. In short, it covers genome-wide microarray testing of germline DNA for copy number variants.

The key clinical boundary is the word “constitutional.” This code applies only when the specimen reflects germline DNA. Typical specimens are peripheral blood, buccal swab, or tissue from a patient whose chromosomal abnormality is expected in every cell. Somatic (acquired) tumor profiling uses different code pathways.

CPT 81228 vs 81229: Key differences coders must know

CPT code 81228 covers copy number analysis only. CPT 81229 adds SNP genotyping to detect loss of heterozygosity (LOH) and uniparental disomy (UPD). Choosing the wrong one is the most common technical billing error on constitutional microarray claims.

In practice: If the laboratory report mentions LOH regions or UPD findings, the platform interrogated single nucleotide polymorphisms, and the correct code is 81229. If the report covers copy number gains and losses only, with no SNP-based LOH or UPD component, 81228 is correct.

When to use CPT 81479 instead of 81228

CPT 81479 is the unlisted molecular pathology procedure code. Use it when the microarray performed doesn’t match the 81228 or 81229 descriptors. Examples include a non-constitutional indication, a research-grade array without clinical validation, or a novel proprietary panel with no specific CPT code.

Billing 81479 requires a cover letter and a special report attached to the claim, explaining what was performed and why no existing code applies. Payers are reluctant to reimburse unlisted codes without this documentation. Some MAC contractors also want the lab’s internal charge, the nearest comparable CPT code, and a clinical reason for not using 81228 or 81229.

• Use 81479 when: The assay is a non-constitutional (somatic or tumor) application of microarray technology that has no specific oncology code.
• Use 81479 when: The platform is a research-only array used in a clinical context as part of an IRB-approved protocol with payer agreement.
• Use 81479 when: The test uses an emerging genomic technology that is not described by 81228 or 81229.
• Do not use 81479 as a fallback if 81228 or 81229 accurately describes the procedure, because payers audit unlisted-code frequency.

Each of the three codes is settled by a question the laboratory report answers, and the questions run in a fixed order.

ICD-10 codes that support medical necessity

The linked ICD-10-CM diagnosis code is how payers decide whether the test was medically necessary. A code missing from the payer’s LCD-approved indication list generates a denial, even when the test was clinically appropriate.

Always verify the exact code against the MAC-specific LCD for your billing jurisdiction before submission. LCD criteria for 81228 vary between Noridian, Palmetto GBA, CGS, and Novitas, so a code one MAC accepts may fail another’s criteria.

When autism is the indication, F84.0 is the usual pairing. Back it with the ordering physician’s evaluation notes, because the LCD review reads the record behind the code.

Medicare coverage and reimbursement

Medicare covers CPT code 81228 under Local Coverage Determinations (LCDs) issued by individual Medicare Administrative Contractors (MACs). There is no national coverage determination (NCD) for constitutional cytogenomic microarray analysis. Coverage rules therefore vary by region, so check the applicable MAC’s LCD before billing.

Reimbursement rates are set annually in the CMS Clinical Laboratory Fee Schedule (CLFS). Payment amounts change each calendar year, so labs should confirm the current-year rate in the fee schedule lookup. Citing a prior-year figure won’t change payment, but budgeting from stale data skews revenue forecasts. The code is billed globally, with no professional or technical component split.

Medicare Advantage (MA) plans follow their own coverage policies, which may differ from traditional Medicare LCDs. MA plans require prior authorization more often than traditional Medicare does. Pabau’s claims software for billers runs real-time eligibility checks through the Claim.MD clearinghouse, so staff can confirm coverage before the specimen is collected.

Prior authorization requirements

Many payers require prior authorization (PA) for CPT code 81228, but requirements vary by payer type, plan, and geography. No blanket rule applies across carriers, so verify each payer’s PA policy individually.

Payer categories and typical PA stance:

• Traditional Medicare: PA is not universally required, but clinical documentation supporting the LCD criteria is mandatory. Some MACs perform post-payment audits on 81228 claims.
• Medicare Advantage: PA is frequently required. MA plans can impose requirements stricter than traditional Medicare, so check the specific plan’s prior authorization list.
• Commercial insurers: Many require PA. Anthem Blue Cross (Virginia) is one example of a commercial payer with a published PA requirement for 81228. Other carriers have similar policies, so always check the payer-specific portal.
• Medicaid: PA requirements and covered indications vary by state. Some state Medicaid programs cover constitutional microarray analysis broadly, while others restrict it to specific diagnostic categories.

Submitting a claim without a required prior authorization is the leading single cause of denials for this code. Labs processing high volumes of 81228 claims should build an eligibility and PA check into order intake, before the specimen is drawn.

Documentation typically required for a PA request:

• Clinical notes from the ordering physician documenting the indication (for example, developmental delay onset or an autism spectrum disorder evaluation)
• Relevant family history and prior genetic testing results
• Ordering provider’s NPI and credentials
• Proposed ICD-10-CM diagnosis codes with clinical justification
• Lab’s CLIA certificate number and NPI
• Statement of medical necessity referencing the applicable LCD criteria

Documentation requirements for a clean claim

A clean claim for CPT code 81228 includes all required fields, passes payer edits, and carries documentation that withstands a medical necessity audit. Each missing item below is a cheap fix before submission and an expensive one after.

• Ordering physician clinical notes documenting the specific indication, symptom onset, and prior workup (karyotype, FISH, fragile X if applicable)
• Signed Advance Beneficiary Notice of Noncoverage (ABN) (Medicare) if the payer may consider the indication non-covered. Obtain it before the specimen is collected.
• CLIA certificate number for the performing laboratory (high-complexity certification required)
• NPI of the ordering provider and the rendering laboratory, both of which must appear on the claim form
• Place of service code 81 when the test is performed by an independent reference laboratory (see the place of service section below)
• Correct ICD-10-CM diagnosis codes that map to the LCD-approved indications for the billing MAC jurisdiction
• PA number if the payer required prior authorization, entered in Box 23 of the CMS-1500
• Laboratory report available in the patient record for potential audit. The report must confirm the constitutional specimen type and the CNV methodology.

Following medical billing compliance protocols means filing this documentation in the patient record before the claim goes out. A clean claim checklist run at submission cuts first-pass denials on complex molecular pathology codes like 81228.

A microarray reports copy number variants and does not count CGG repeats, so fragile X testing runs as its own PCR assay. The lab bills that assay as 81243, the FMR1 code for evaluating whether an allele is expanded.

Place of service, modifier, and billing unit rules

These technical parameters delay payment when they’re wrong, even if the clinical documentation is sound.

Common denial reasons and how to appeal

Denials on CPT code 81228 cluster around five root causes. Fixing each one before submission costs less than appealing it afterward.

Tracking denial patterns across 81228 claims shows revenue cycle teams which issues are systemic. Our denial codes guide explains the CARC reason codes most often attached to molecular pathology denials. For appeal timelines and escalation, the denial management guide applies to 81228 and other high-scrutiny genetic tests.

How claims management software prevents 81228 denials

Without a check before submission, a missing PA or a mismatched ICD-10 code only surfaces when the remittance comes back. By then the test has been run, and retro-authorization rarely rescues the claim.

Pabau connects to the Claim.MD clearinghouse, so eligibility checks and claim scrubbing happen before the claim goes out. The scrub validates CPT and ICD-10 codes and flags a missing PA before the claim reaches the payer.

ERA remittances, denial reasons included, come back into the same billing workflow. Your team sees which 81228 claims were denied and why, so the monthly denial review starts from data already in the system.

Reduce claim denials on molecular pathology codes

Pabau connects to the Claim.MD clearinghouse to validate CPT and ICD-10 codes, run real-time eligibility checks, and track ERA remittances. Your team catches 81228 issues before the payer does.

Book a demo

Conclusion

The work on 81228 happens before the specimen is drawn. Confirm the PA, match the diagnosis to your MAC’s LCD, and read the lab report for LOH or UPD before choosing between 81228 and 81229.

Building those checks into intake adds a step to every order. On a code where retro-authorization rarely succeeds, that step costs far less than the denials it prevents.

Pabau’s insurance eligibility verification workflow confirms coverage and flags PA requirements at intake. Book a demo to see how it keeps 81228 claims clean in a high-volume genetic testing practice.

Continue your research

Need to understand how clearinghouses process molecular pathology claims? Medical claims clearinghouse guide explains how 837P electronic submissions flow from practice to payer.

Billing 81228 alongside other genetic codes? 837 EDI file structure covers how CPT codes are transmitted in electronic claim files and where sequencing errors cause rejections.

Getting ERA remittances back with denial reason codes? Electronic remittance advice (ERA) explained breaks down how to read CARC and RARC codes on 835 transactions.

Coding a developmental delay indication? ICD-10 code R62.50 covers unspecified lack of expected normal physiological development in childhood.

Frequently asked questions